Read more about Intas Pharma files draft prospectus for IPO on Business Standard. Drug maker Intas Pharmaceuticals today said it has filed. Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public. Intas Pharma DRHP News: Latest and Breaking News on Intas Pharma DRHP. Explore Intas Pharma DRHP profile at Times of India for photos, videos and latest .
|Published (Last):||9 December 2005|
|PDF File Size:||2.31 Mb|
|ePub File Size:||15.89 Mb|
|Price:||Free* [*Free Regsitration Required]|
Web Interface Conceived and Powered By: Chandra kicks off divestment plan. ChrysCap backs Curatio in latest pharma bet. Its products are marketed in over 60 countries, either directly, through its subsidiaries or indirectly, through supply, distribution and other arrangements with various leading global pharmaceutical companies. Intas Pharma merges group companies, subsidiaries.
Intas to buy Teva’s UK, Ireland assets for mn pounds. In what could further strengthen its business in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum. Monday, 31 December Intas Pharma eyes hospitals in Europe, US. It has also extended its presence into other therapy areas such as gynecology, infertility, arthritis and the respiratory.
The company is present in various major therapy areas such as those relating to neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, oncology, critical care and ophthalmology with a strong focus on chronic therapy areas relating to neurology, psychiatry, cardiology and diabetology. MCI to probe foreign jaunts by MP doctors. We will get in touch with you shortly.
Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about low profits. New Delhi, May 26 RPG Life Sciences has sold its Gujarat-based biotechnology unit to Intas Pharmaceuticals for Rs 25 crore to focus on core areas of business and improve long-term competitiveness in a rapidly changing market.
Medical Council of India MCI will investigate a complaint against 11 doctors from Madhya Pradesh who are charged with accepting foreign jaunts sponsored by pharmaceutical company. Drugs sold sans regulator’s nod, safety studies.
Intas Pharmaceuticals files DRHP for IPO
It is currently ranked as the 12th largest pharmaceutical company in the country with a 2. Mon, Dec 31, Updated Nimish Hasmukhbhai Chudgar, Dr. Please fill the all fields. Intas Pharma is a vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulation.
Please click here to Sign-in or Sign-up. Subscribe to BioSpectrum India. At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop.
Intas Pharma files for an IPO
Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs crore. Desi pharma companies top in biosimilars globally. Binish Hasmukh Chudgar, Mr. Intas Pharma drbp first etanercept biosimilar. Enquiry Thanks for contacting us!
According to sources, the company has begun the groundwork for the IPO and approached merchant bankers a couple of months ago. The promoters of the company are Mr. Please note that comments are moderated and are generally published if they are on-topic and not abusive.
The Ahmedabad-based company is considering licensing agreements with hospital-based businesses in these markets. Email Enter a valid email address.
Intas Pharma files draft prospectus for IPO | Business Standard News
Sources said the group has started a process to sell drug discovery services company Advinus Therapeutics, drawing interest from private equity funds Kedaara Capital and True North as well as from strategic players, GVK Biosciences and Lambda, a unit of Intas Pharma. All rights reserved Disclaimer.
Rrhp Pharma buys Spanish company’s hospital business. From around the Web. The IPO will be made through a public issue of equity shares of face value of Rs.